ATNX
Athenex, Inc.
About ATNX
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. The Company operates through three segments: Oncology Innovation Platform, which is engaged in the research and development of its drugs; Commercial Platform, which is focused on the sales and marketing of its specialty drugs and the market development of its drugs; and Global Supply Chain Platform, providing sterile injectable drugs to hospital pharmacies across the U.S. The Company’s clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting GD2 (GINAKIT cells).
Buy US stocks in Australia starting with ATNX. Open an account and start investing today!
$34.79M
-
0.00%
23.42K
$0.24
$0.21
$0.00
$1.20
$0.12
ATNX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ATNX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.